| Budget Amount *help |
¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2019: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we aimed to non-invasively identify the tissue-specific properties of human iPS cell-derived cardiomyocytes using motion vector analysis. We demonstrated that commercially available human iPS cell-derived cardiomyocytes have diverse properties by examining the contractile functions of cells that have been dyed by antibody immunostaining against an atrial muscle marker and a ventricular muscle marker. It was found that the contraction speed and relaxation speed of atrial-type was faster than those of ventricular-type. This result was in the same tendency as the difference observed in mouse atrial myocytes and ventricular myocytes, and there was a difference in the reactivity among different class of cardiovascular reagents. From the above, we have developed a novel experimental system that can non-invasively evaluate the drug actions.
|
